查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1672647

慢性腎臟病腎病藥物市場：依藥物類別、給藥途徑、適應症、通路及地區分類

Chronic Kidney Disease Drugs Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 206 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2025 年全球慢性腎臟病藥物市場規模估計為 159.2 億美元，預計 2032 年將達到 230.2 億美元，2025 年至 2032 年的複合年成長率為 5.4%。

報告範圍 報告詳細資訊
基準年 2024 2025 年市場規模 159.2億美元
效能資料 從 2020 年到 2024 年 預測期 2025 至 2032 年
預測期：2025-2032年複合年成長率： 5.40% 2032 年價值預測 230.2億美元
數字。 2025 年慢性腎臟病藥物市場佔有率（按地區分類）
慢性腎臟病藥物市場-IMG1

全球慢性腎臟病藥物市場的成長是由世界各地腎臟疾病盛行率的不斷上升所推動的。慢性腎臟病（CKD）是指腎功能隨著時間的推移而逐漸衰退。如果不及時治療，CKD最終會導致腎衰竭和末期腎病變。 CKD 的常見原因包括糖尿病、高血壓、腎絲球腎炎和多囊性腎病變。老年人口的增加和文明病的增加有可能導致CKD盛行率的上升。慢性腎臟病藥物旨在減緩病情進展、治療併發症並維持整體腎臟健康。腎素-血管收縮素系統抑制劑、鈣通道阻斷劑、紅血球生成素促效劑和利尿劑是治療慢性腎臟病的主要藥物類別。

市場動態：

全球慢性腎臟病藥物市場的成長受到糖尿病和高血壓盛行率上升的推動。根據國際糖尿病聯盟發布的資料，2021年全球約有5.37億成年人患有糖尿病。預計到 2030 年這一數字將成長到 6.43 億，到 2045 年將成長到 7.83 億。高血壓也是 CKD 的主要原因。政府積極採取措施，傳播有關腎臟疾病早期診斷和治療的意識，可能會推動市場成長。然而，新藥認證的嚴格規定以及長期治療相關的嚴重副作用的風險可能會阻礙市場的成長。聯合治療標靶治療的發展為慢性腎臟病藥物行業的製造商提供了有利可圖的機會。

本研究的主要特點

本報告對全球慢性腎臟病藥物市場進行了詳細分析，並提供了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設 2024 年為基準年。

它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。

它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。

全球慢性腎臟病治療藥物市場的主要企業根據公司亮點、產品系列、關鍵亮點、績效和策略等參數進行分析。

本研究涉及的主要企業包括輝瑞公司、葛蘭素史克公司、羅氏公司、賽諾菲、Keryx 生物製藥、Kissei 製藥有限公司、阿斯特捷利康公司和 Teva 製藥工業有限公司。

本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。

全球慢性腎臟病治療藥物市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員可以透過用於分析全球慢性腎臟病治療市場的各種策略矩陣來促進決策。

目錄

第1章 調查目的與前提條件

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告描述
    • 市場定義和範圍
  • 執行摘要

第3章市場動態、法規與趨勢分析

  • 市場動態
  • 影響分析
  • 主要亮點
  • 監管情景
  • 產品發布/核准
  • PEST分析
  • PORTER 分析
  • 併購情景

4. 2020 年至 2032 年全球慢性腎臟病藥物市場（按藥物類別分類）（十億美元）

  • 血管緊張素轉換酶 (ACE) 抑制劑
  • 血管收縮素素受體阻斷劑 (ARB)
  • B阻斷劑
  • 鈣離子通道阻斷劑
  • 袢利尿劑
  • 促紅血球生成素促效劑 (ESA)
  • 磷酸鹽粘合劑
  • 其他

5. 2020 年至 2032 年按給藥途徑分類的全球慢性腎臟病藥物市場（十億美元）

  • 口服
  • 腸外

6. 2020 年至 2032 年全球慢性腎臟病藥物市場（依適應症分類）（十億美元）

  • 糖尿病腎臟病
  • 腎絲球腎炎
  • 高血壓腎臟病
  • 多囊腎
  • 其他適應症

7. 2020-2032 年全球慢性腎臟病藥物市場按分銷管道分類（十億美元）

  • 醫院藥房
  • 零售藥局
  • 網路藥局

8. 2020 年至 2032 年全球慢性腎臟病藥物市場（按地區分類）（十億美元）

  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章 競爭格局

  • AstraZeneca
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Sanofi
  • GlaxoSmithKline plc（GSK）
  • AbbVie Inc.
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Reata Pharmaceuticals, Inc.
  • Ardelyx, Inc.
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/S
  • Novartis AG
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Akebia Therapeutics, Inc.

第 10 章分析師建議

  • 命運之輪
  • 分析師觀點
  • 一致的機會地圖

第 11 章 參考文獻與調查方法

  • 參考
  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI1713

Global Chronic Kidney Disease Drugs Market is estimated to be valued at USD 15.92 Bn in 2025 and is expected to reach USD 23.02 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 15.92 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.40% 2032 Value Projection: USD 23.02 Bn
Figure. Chronic Kidney Disease Drugs Market Share (%), By Region 2025
Chronic Kidney Disease Drugs Market - IMG1

Global chronic kidney disease drugs market h growth is driven by rising prevalence of kidney disorders worldwide. Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time. If left untreated, CKD can eventually lead to kidney failure or end-stage renal disease. Some of the common causes of CKD include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease. Growing geriatric populations and increasing lifestyle diseases can lead to increased prevalence of CKD. The chronic kidney disease drugs aim to slow down the progression of the disease, treat complications, and help maintain overall kidney health. Renin-angiotensin system inhibitors, calcium channel blockers, erythropoiesis-stimulating agents, and diuretics are some of the major drug classes used for managing chronic kidney diseases.

Market Dynamics:

Global chronic kidney disease drugs market growth is driven by rising prevalence of diabetes and hypertension as both are significant risk factors for CKD. According to the data published by the International Diabetes Federation, nearly 537 million adults lived with diabetes in 2021 across the globe. This number is anticipated to rise to 643 million by 2030 and 783 million by 2045. High blood pressure, or hypertension, is also a major culprit for CKD cases. Favorable government initiatives to spread awareness about early diagnosis and treatment of kidney diseases can drive the market growth. However, stringent regulations for new drug approval and the risk of severe side effects associated with long-term therapy can hamper the market growth. The development of combinational and targeted therapies presents lucrative opportunities for manufacturers in the chronic kidney disease drugs industry.

Key features of the study:

This report provides in-depth analysis of the global chronic kidney disease drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic kidney disease drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi, Keryx Biopharmaceuticals, Kissei Pharmaceutical Co. Ltd., AstraZeneca plc, Teva Pharmaceutical Industries Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market

Detailed Segmentation-

  • By Drug Class
    • ACE Inhibitors
    • Angiotensin Receptor Blockers (ARBs)
    • B-Blockers
    • Calcium Channel Blockers
    • Loop Diuretics
    • Erythropoiesis-Stimulating Agents (ESAs)
    • Phosphate Binders
    • Others
  • By Route of Administration:
    • Oral
    • Parenteral
  • By Indication
    • Diabetic Nephropathy
    • Glomerulonephritis
    • Hypertensive Nephropathy
    • Polycystic Kidney Disease
    • Other Indications
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Key Players Insights
    • AstraZeneca
    • Amgen Inc.
    • Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Sanofi
    • GlaxoSmithKline plc (GSK)
    • AbbVie Inc.
    • Keryx Biopharmaceuticals, Inc.
    • Kissei Pharmaceutical Co., Ltd.
    • Regeneron Pharmaceuticals, Inc.
    • Bayer AG
    • Reata Pharmaceuticals, Inc.
    • Ardelyx, Inc.
    • Boehringer Ingelheim International GmbH
    • Novo Nordisk A/S
    • Novartis AG
    • Johnson & Johnson
    • Astellas Pharma Inc.
    • Takeda Pharmaceutical Company Limited
    • Akebia Therapeutics, Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Chronic Kidney Disease Drugs Market, By Drug Class
    • Global Chronic Kidney Disease Drugs Market, By Route of Administration
    • Global Chronic Kidney Disease Drugs Market, By Indication
    • Global Chronic Kidney Disease Drugs Market, By Distribution Channel
    • Global Chronic Kidney Disease Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • ACE Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Angiotensin Receptor Blockers (ARBs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • B-Blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Calcium Channel Blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Loop Diuretics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Erythropoiesis-Stimulating Agents (ESAs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Phosphate Binders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Chronic Kidney Disease Drugs Market, By Route of Administration, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Parentral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Chronic Kidney Disease Drugs Market, By Indication, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Diabetic Nephropathy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Glomerulonephritis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hypertensive Nephropathy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Polycystic Kidney Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Other Indications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Chronic Kidney Disease Drugs Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2020 - 2032, (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
    • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

9. Competitive Landscape

  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • F. Hoffmann-La Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi
  • GlaxoSmithKline plc (GSK)
  • AbbVie Inc.
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Reata Pharmaceuticals, Inc.
  • Ardelyx, Inc.
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/S
  • Novartis AG
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Akebia Therapeutics, Inc.

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us